- Home
- GPRK vs ALDX Comparison
GPRK vs ALDX Comparison
Compare GPRK & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- ALDX
- Stock Information
- Founded
- GPRK 2002
- ALDX 2004
- Country
- GPRK Colombia
- ALDX United States
- Employees
- GPRK N/A
- ALDX N/A
- Industry
- GPRK Oil & Gas Production
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- ALDX Health Care
- Exchange
- GPRK Nasdaq
- ALDX Nasdaq
- Market Cap
- GPRK 335.7M
- ALDX 270.7M
- IPO Year
- GPRK N/A
- ALDX 2014
- Fundamental
- Price
- GPRK $6.66
- ALDX $5.39
- Analyst Decision
- GPRK Buy
- ALDX Strong Buy
- Analyst Count
- GPRK 1
- ALDX 2
- Target Price
- GPRK $11.00
- ALDX $9.50
- AVG Volume (30 Days)
- GPRK 589.7K
- ALDX 1.0M
- Earning Date
- GPRK 08-05-2025
- ALDX 08-07-2025
- Dividend Yield
- GPRK 8.83%
- ALDX N/A
- EPS Growth
- GPRK N/A
- ALDX N/A
- EPS
- GPRK 0.81
- ALDX N/A
- Revenue
- GPRK $560,354,000.00
- ALDX N/A
- Revenue This Year
- GPRK N/A
- ALDX N/A
- Revenue Next Year
- GPRK $3.01
- ALDX $29.89
- P/E Ratio
- GPRK $8.26
- ALDX N/A
- Revenue Growth
- GPRK N/A
- ALDX N/A
- 52 Week Low
- GPRK $5.66
- ALDX $1.14
- 52 Week High
- GPRK $11.72
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- GPRK 48.50
- ALDX 64.33
- Support Level
- GPRK $6.50
- ALDX $5.21
- Resistance Level
- GPRK $6.87
- ALDX $5.35
- Average True Range (ATR)
- GPRK 0.24
- ALDX 0.29
- MACD
- GPRK 0.02
- ALDX -0.04
- Stochastic Oscillator
- GPRK 66.42
- ALDX 92.06
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.